Assessment on the short-term curative effects of docetaxe and prednisone combined with disodium clodronate in the treatment of hormone-refractory prostate cancer

Abstract:

Objective：To explore the short-term curative effects and side effects of docetaxe and prednisone combined with disodium clodronate in the treatment of hormone refractory prostate cancer（HRPC）. Methods：Twenty-six patients with HRPC were enrolled in this study and received the following treatments：docetaxe（75 mg/m2，intravenously） on d1；prednisone（5 mg twice per day，preorally） on d1-d21 and disodium clodronate（one pill twice per day） on on d1-d21. After a 3-week cycle，the parameters of total prostate spe－cific antigen（TPSA），pain score，bone mineral density and measurable metastasis were examed after the chemotherapy cycle and the side effects being observed. Results：Of the 26 patients，TPSA was decreased in 17 patients（65.4%）. Among 26 patients with bone pain，remarkable pain relief was seen in 21 patients and the average numeric rating scale was decreased from 5.13 to 2.8. After the chemotherapy，the maximum diameter of metastatic tumor was reduced significantly in 6 out of 10 patients. The side effects of the chemotherapy were mainly myelosuppression，hand-foot syndrome and gastrointestinal reactions. Conclusion：The docetaxel-pred－nisone-disodium clodronate combination regime is effective and tolerable in the treatment for advanced hormone- refractory prostate cancer.